Is IRadimed Corp. overvalued or undervalued?

As of 31 October 2025, the valuation grade for IRadimed Corp. has moved from attractive to fair, indicating a shift in its perceived value. The company is currently fairly valued based on its financial metrics. The P/E ratio stands at 39, while the Price to Book Value is 8.54, and the EV to EBITDA ratio is 30.68.
In comparison to its peers, IRadimed Corp. has a P/E ratio of 44.24, which is higher than the industry average, suggesting it may be overvalued relative to its competitors. For instance, Artivion, Inc. has a negative P/E ratio, while BioLife Solutions, Inc. also shows a negative figure, indicating challenges in those companies. Despite this, IRadimed Corp. has demonstrated strong returns, with a year-to-date return of 39.65% compared to the S&P 500's 16.30%, and a 5-year return of 239.12% against the S&P 500's 109.18%.